학술논문
63PD - Predictive and pharmacodynamic biomarkers associated with phase II, selective and orally bioavailable AXL inhibitor bemcentinib across multiple clinical trials
Document Type
Abstract
Author
Source
In Annals of Oncology October 2018 29 Supplement 8
Subject
Language
ISSN
0923-7534